First GSK milestone for Isis as antisense amyloidosis drug progresses
This article was originally published in Scrip
Executive Summary
With the initiation of a Phase II/III clinical trial for the antisense drug ISIS-TTRRx as a treatment for transthyretin (TTR) amyloidosis Isis Pharmaceuticals earned a $7.5 million milestone payment from GlaxoSmithKline under the companies' 2010 alliance to develop RNA therapeutics for rare and infectious diseases.